CAJ | 학술논문

目的探讨超脉冲CO2激光治疗结节性硬化患者面部血管纤维瘤临床疗效、不良反应及复发率.方法回顾性分析了结节性硬化面部血管纤维瘤患者36例,采用超脉冲CO2激光治疗并根据皮损类型选择治疗参数.结果 36例结节性硬化症面部血管纤维瘤患者与治疗前相比,28例患者单次治疗痊愈10例,显效10例,有效5例,无效3例,复发18例,有效率89.3％,显效率71.4％,复发率64.3％.原发皮损较少且分布较稀疏的患者疗效较好.治疗有效率与年龄、性别、病史的相关性无统计学意义(均P＞0.05).36例患者均无永久性色素沉着、色素减退、萎缩及增生性瘢痕.结论超脉冲CO2激光治疗结节性硬化患者面部血管纤维瘤有效,不良反应少,但容易复发.原发皮损数量少者疗效好.
목적 탐토초맥충CO2격광치료결절성경화환자면부혈관섬유류림상료효、불량반응급복발솔.방법 회고성분석료결절성경화면부혈관섬유류환자36례,채용초맥충CO2격광치료병근거피손류형선택치료삼수.결과 36례결절성경화증면부혈관섬유류환자여치료전상비,28례환자단차치료전유10례,현효10례,유효5례,무효3례,복발18례,유효솔89.3％,현효솔71.4％,복발솔64.3％.원발피손교소차분포교희소적환자료효교호.치료유효솔여년령、성별、병사적상관성무통계학의의(균P＞0.05).36례환자균무영구성색소침착、색소감퇴、위축급증생성반흔.결론 초맥충CO2격광치료결절성경화환자면부혈관섬유류유효,불량반응소,단용역복발.원발피손수량소자료효호.
Objective To estimate the clinical efficacy and adverse effects of ultrapulse carbon dioxide laser for the treatment of facial angiofibroma in tuberous sclerosis patients,and to observe the recurrence of facial angiofibroma in the patients after treatment with ultrapulse carbon dioxide laser.Methods Thirty-six tuberous sclerosis patients with facial angiofibroma were enrolled in this study.Ultrapulse carbon dioxide laser (Ultrapulse Encore) was used for the treatment of facial angiofibroma in these patients.Laser parameters were selected according to the type of skin lesions.Results Finally,28 patients who received single irradiation treatment and completed 6-month follow up were evaluated for efficacy and safety.Of the 28 patients,10 were cured,10 showed marked response,5 response,3 no response,and 18 experienced recurrence,with the response rate,marked response rate and recurrence rate being 89.3％,71.4％ and 64.3％ respectively.Patients with a relatively small number of sparsely distributed primary lesions showed a relatively good response.There was no significant correlation between the response rate and patients' age,gender or medical history (all P ＞ 0.05).No permanent pigmentation,depigmentation,atrophy or hyperplastic scar was observed in any of these 36 patients.Conclusions Ultrapulse carbon dioxide laser is effective for the treatment of facial angiofibroma in tuberous sclerosis patients with few adverse effects but high recurrence risk.There seems to be a relatively good response to ultrapulse carbon dioxide laser in patients with a small number of primary lesions.